Relevant Aspects of Drug Genetic Toxicology

Genotoxic lesions are not only a cause of genetic pathologies and cancer, but also the most common and significant factor of the etiopathology of cardiovascular and neurodegenerative disorders, reproductive losses, infertility, and aging. This requires careful monitoring of the use of potential genotoxicants including medicinal products (MPs), which are a group of compounds intentionally and routinely used by humans. Genotoxicity assesment is highly essential in preclinical drug safety studies. The aim of the study was to analyse the current situation and reveal possible ways of addressing methodological and regulatory issues in genotoxicology to enable proper conduction of drug safety preclinical studies. The article summarises basic concepts of the modern genetic toxicology development and highlights the history of research aimed at identifying mutagenic, clastogenic, and aneugenic effects. The authors analyse regulatory aspects of genotoxicological studies of MPs and consider issues of improving the strategy for genotoxicity testing. The paper gives information about the genotoxicity tests approved for MPs, recommendations for interchangeability of tests in relation to particular study characteristics. The authors carried out a comparative analysis of the tests’ pros and cons with an emphasis that the study of each MP is a separate scientific task. They discuss interpretation of results and prediction of MP carcinogenic potential in genotoxicological studies. Recommendations are given for the optimisation of the MP genotoxicity assessment strategy, considering its partial integration into general toxicity studies. The article stresses the urgent need to develop registration methods for genotoxic events in germ cells, assesses the prospects of new tests, and reviews new trends in drug genotoxicology fundamental research.

1. Durnev AD, Zhanataev AK, Shreder OV, Seredenina VS. Genotoxic events and diseases sicheskie. Molekulyarnaya meditsina = Molecular Medicine. 2013;(3):3–19 (In Russ.)

2. Choudhuri S, Kaur T, Jain S, Sharma C, Asthana S. A review on genotoxicity in connection to infertility and cancer. Chem Biol Interact. 2021;345:109531. https://doi.org/10.1016/j.cbi.2021.109531

3. Dearfield KL, Cimino MC, McCarroll NE, Mauer I, Valcovic LR. Genotoxicity risk assessment: a proposed classification strategy. Mutat Res. 2002;521(1–2):121– 35. https://doi.org/10.1016/s1383-5718(02)00236-x

4. Durnev AD. Genetic toxicology. Vestnik RAMN = Annals of the Russian Academy of Medical Sciences. 2011;(9):35–44 (In Russ.)

5. Ames BN, Gold LS. Endogenous mutagens and the causes of aging and cancer. Mutat Res. 1991;250(1– 2):3–16. https://doi.org/10.1016/0027-5107(91)90157-j

6. Bochkov NP, Shram RI, Kuleshov NP, Zhurkov VS. Human chemical assessment system: general principles, practical recommendations and further developments. Genetika = Genetics. 1975;11(10):156–69 (In Russ.)

7. Bridges BA. Some general principles of mutagenicity screening and possible framework for testing procedure. Environ Health Perspect. 1973;6:221–7. https://doi.org/10.1289/ehp.7306221

8. Steiblen G, Benthem JV, Johnson G. Strategies in genotoxicology: acceptance of innovative scientific methods in a regulatory context and from an industrial perspective. Mutat Res Genet Toxicol Environ Mutagen. 2020;853:503171. https://doi.org/10.1016/j.mrgentox.2020.503171

9. Müller L, Tweats D, Galloway S, Hayashi M. The evolution, scientific reasoning and use of ICH S2 guidelines for genotoxicity testing of pharmaceuticals. In: van der Laan JW, DeGeorge JJ, eds. Global Approach in Safety Testing: ICH Guidelines Explained. Springer; 2013.

10. Baldrick P. Genotoxicity test battery — an assessment of its utility in early drug development. Mutat Res Genet Toxicol Environ Mutagen. 2021;868–869:503388. https://doi.org/10.1016/j.mrgentox.2021.503388

11. Richmond J. Refinement, reduction, and replacement of animal use for regulatory testing: future improvements and implementation within the regulatory framework. ILAR J. 2002;43 Suppl:S63–8. https://doi.org/10.1093/ilar.43.suppl_1.s63

12. McCann J, Ames BN. Detection of carcinogens as mutagens in the Salmonella microsome test: assay of 300 chemicals: discussion. Proc Nat Acad Sci USA. 1976;73(3):950–4. https://doi.org/10.1073/pnas.73.3.950

13. McCann J, Choi E, Yamasaki E, Ames BN. Detection of carcinogens as mutagens in the Salmonella/ microsome test: assay of 300 chemicals: discussion. Proc Nat Acad Sci USA. 1975;72(12):5135–9. https://doi.org/10.1073/pnas.72.12.5135

14. Kirkland D, Aardema M, Henderson L, Muller L. Evaluation of the ability of a battery of three in vitro genotoxicity tests to discriminate rodent carcinogens and non-carcinogens I. Sensitivity, specificity and relative predictivity. Mutat Res. 2005;584(1–2):1–256. https://doi.org/10.1016/j.mrgentox.2005.02.004

15. Kirkland D, Pfuhler S, Tweats D, Aardema M, Corvi R, Darroudi F, et al. How to reduce false positive results when undertaking in vitro genotoxicity testing and thus avoid unnecessary follow-up animal tests: report of an ECVAM workshop. Mutat Res. 2007;628(1):31–55. https://doi.org/10.1016/j.mrgentox.2006.11.008

16. Fischer I, Milton C, Wallace H. Toxicity testing is evolving! Toxicol Res (Camb). 2020;9(2):67–80. https://doi.org/10.1093/toxres/tfaa011

17. Dertinger SD, Bhalli JA, Roberts DJ, Stankowski LF, Gollapudi BB, Lovell DP, et al. Recommendations for conducting the rodent erythrocyte Pig–a assay: a report from the HESI GTTC Pig–a Workgroup. Environ Mol Mutagen. 2021;62(3):227–37. https://doi.org/10.1002/em.22427

18. Salk JJ, Kennedy SR. Next-generation genotoxicology: using modern sequencing technologies to assess somatic mutagenesis and cancer risk. Environ Mol Mutagen. 2020;61(1):135–51. https://doi.org/10.1002/em.22342

19. Heflich RH, Johnson GE, Zeller A, Marchetti F, Douglas GR, Witt KL, et al. Mutation as a toxicological endpoint for regulatory decision-making. Environ Mol Mutagen. 2020;61(1):34–41. https://doi.org/10.1002/em.22338

20. Morita T, Hamada S, Masumura K. Evaluation of the sensitivity and specificity of in vivo erythrocyte micronucleus and transgenic rodent gene mutation tests to detect rodent carcinogens. Mutat Res Genet Toxicol Environ Mutagen. 2016;802:1–29. https://doi.org/10.1016/j.mrgentox.2016.03.008

21. Kirkland D, Zeiger E, Madia F, Corvi R. Can in vitro mammalian cell genotoxicity test results be used to complement positive results in the Ames test and help predict carcinogenic or in vivo genotoxic activity? II. Construction and analysis of a consolidated database. Mutat Res Genet Toxicol Environ Mutagen. 2014;775–776:69–80. https://doi.org/10.1016/j.mrgentox.2014.10.006

22. Kirkland D, Uno Y, Luijten M, Beevers C, van Benthem J, Burlinson B, et al. In vivo genotoxicity testing strategies: Report from the 7th International workshop on genotoxicity testing (IWGT). Mutat Res Genet Toxicol Environ Mutagen. 2019;847:403035. https://doi.org/10.1016/j.mrgentox.2019.03.008

23. Elespuru R, Pfuhler S, Aardema MJ, Chen T, Doak SH, Doherty A, et al. Genotoxicity assessment of nanomaterials: recommendations on best practices, assays, and methods. Toxicol Sci. 2018;164(2):391–416. https://doi.org/10.1093/toxsci/kfy100

24. Goodman JI. Goodbye to the bioassay. Toxicol Res (Camb). 2018;7(4):558–64. Erratum in: Toxicol Res (Camb). 2018;7(5):994. https://doi.org/10.1039/c8tx00004b

25. MacGregor JT, Frötschl R, White PA, Crump KS, Eastmond DA, Fukushima S, et al. IWGT report on quantitative approaches to genotoxicity risk assessment I. Methods and metrics for defining exposure-response relationships and points of departure (PoDs). Mutat Res Genet Toxicol Environ Mutagen. 2015;783:55–65. https://doi.org/10.1016/j.mrgentox.2014.09.011

26. Adler ID, Ashby J. The present lack of evidence for unique rodent germ-cell mutagens, Mutat. Res. 1989;212(1):55– 66. https://doi.org/10.1016/0027-5107(89)90022-5

27. Yauk CL, Aardema MJ, Benthem J, Bishop JB, Dearfield KL, DeMarini DM, et al. Approaches for identifying germ cell mutagens: report of the 2013 IWGT workshop on germ cell assays. Mutat Res Genet Toxicol Environ Mutagen. 2015;783:36–54. https://doi.org/10.1016/j.mrgentox.2015.01.008

28. Durnev AD. Analysis and importance of germ cells mutations. Meditsinskaya genetika = Medical Genetics. 2011;(2):3–11 (In Russ.)

29. Adler ID, Carere A, Eichenlaub-Ritter U, Pacchierotti F. Gender differences in the induction of chromosomal aberrations and gene mutations in rodent germ cells. Environ Res. 2007;104(1):37–45. https://doi.org/10.1016/j.envres.2006.08.010

30. Sudman PD, Generoso WM. Female-specific chemical mutagens. Environ Mol Mutagen. 1990;15 Suppl 17:58.

31. Pligina KL, Zhanataev AK, Chaika ZV, Durnev AD. Method of cytogenic assay of mouse oocytes. Bulleten eksperimentalnoy biologii i meditsiny = Bulletin of Experimental Biology and Medicine. 2013;156(7):128–32 (In Russ.)

32. Turpaev KT. Keap1-Nrf2 signaling pathway: mechanisms of regulation and role in protection of cells against toxicity caused by xenobiotics and electrophiles. Biokhimiya = Biochemistry. 2013;78(2):147–66 (In Russ.)

33. Shaw P, Chattopadhyay A. Nrf2-ARE signaling in cellular protection: Mechanism of action and the regulatory mechanisms. J Cell Physiol. 2020;235(4):3119– 30. https://doi.org/10.1002/jcp.29219

34. Durnev AD. Antimutagenesis and antimutagens. Fiziologiya cheloveka = Human Physiology. 2018;44(3):116–37 (In Russ.) https://doi.org/10.7868/S013116461803013X

35. Durnev AD. Pharmacology of mutagenesis. Eksperimental’naya i klinicheskaya farmakologiya = Experimental and Clinical Pharmacology. 2021;84(2):8–14 (In Russ.) https://doi.org/10.30906/0869-2092-2021-84-2-8-14

36. Durnev AD, Seredenin SB. Mutagens: screening and pharmacological prevention of exposures. Moscow: Meditsina; 1998 (In Russ.)

37. Durnev AD, Seredenin SB. Co-mutagenesis as new vistas in genotoxicology. Bulleten eksperimentalnoy biologii i meditsiny = Bulletin of Experimental Biology and Medicine. 2003;135(6):604–12 (In Russ.)

38. Durnev AD, Daugel’-Dauge NO, Seredenin SB. Comutagen interaction of verapamil and ribavirin. Eksperimental’naya i klinicheskaya farmakologiya = Experimental and Clinical Pharmacology. 2006;69(1):56–9 (In Russ.)

39. Durnev AD, Daugel’-Dauge NO, Zhanataev AK, Lapitskaya AS, Seredenin SB. Comutagenic effects of valocordin. Ekologicheskaya genetika = Ecological Genetics. 2012;10(3):53–8 (In Russ.)

40. Durnev AD, Kulakova AV, Zhanataev AK, Oganesyants LA. Evaluation of the cytogenetic and mutagen-modifying activity of caffeine in mouse bone marrow cells. Gigiena i sanitariya = Hygiene and Sanitation. 2015;94(3):106–10 (In Russ.)

41. Brambilla G, Mattioli F, Robbiano L, Martelli A. Genotoxicity and carcinogenicity studies of bronchodilators and antiasthma drugs. Basic Clin Pharmacol Toxicol. 2013;112(5):302–13. https://doi.org/10.1111/bcpt.12054

42. Eremina NV, Zhanataev AK, Lisitsyn AA, Durnev AD. Genotoxic properties of hypoglycemic drugs (systematic review). Ekologicheskaya genetika = Ecological Genetics. 2021;19(3):219–40 (In Russ.) https://doi.org/10.17816/ecogen70691

43. Durnev AD, Eremina NV, Zhanataev AK, Kolik LG. Genotoxicity of psychotropic drugs in experimental and clinical studies (article is being published) (In Russ.)